1. P-332A new prognostic score for biliary tract cancer: a multicenter experience. (2nd July 2019) Authors: Ziranu, P; Lai, E; Casadei Gardini, A; Pretta, A; Faloppi, L; Andrikou, K; Astara, G; Orsi, G; Impera, V; Mariani, S; Liscia, N; Soro, P; Musio, F; Camera, S; Tolu, S; Madeddu, C; Massa, E; Pusceddu, V; Demurtas, L; Puzzoni, M Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P-296Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience. (2nd July 2019) Authors: Pretta, A; Lai, E; Liscia, N; Impera, V; Camera, S; Musio, F; Mariani, S; Soro, P; Persano, M; Donisi, C; Tolu, S; Balconi, F; Atzori, F; Dessì, M; Massa, E; Madeddu, C; Pusceddu, V; Astara, G; Demurtas, L; Puzzoni, M Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P-230Effectiveness of CA 19.9 in predicting prognosis in metastatic pancreatic cancer patients treated with nab-paclitaxel plus gemcitabine. (2nd July 2019) Authors: Mariani, S; Soro, P; Liscia, N; Balconi, F; Camera, S; Donisi, C; Impera, V; Musio, F; Persano, M; Pireddu, A; Pretta, A; Tolu, S; Pusceddu, V; Lai, E; Faloppi, L; Demurtas, L; Ziranu, P; Puzzoni, M; Scartozzi, M Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P-209P 53 abnormal expression might influence global outcome through EGFR modulation in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan cetuximab. (20th June 2018) Authors: Puzzoni, M; Demurtas, L; Ziranu, P; Lai, E; Giampieri, R; Faloppi, L; Mandolesi, A; Cremolini, C; Masi, G; Gelsomino, F; Mariani, S; Cubeddu, A; Casula, L; Liscia, N; Pusceddu, V; Antoniotti, C; Loretelli, C; Meriggi, F; Zaniboni, A; Falcone, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P-209P 53 abnormal expression might influence global outcome through EGFR modulation in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan cetuximab. (20th June 2018) Authors: Puzzoni, M; Demurtas, L; Ziranu, P; Lai, E; Giampieri, R; Faloppi, L; Mandolesi, A; Cremolini, C; Masi, G; Gelsomino, F; Mariani, S; Cubeddu, A; Casula, L; Liscia, N; Pusceddu, V; Antoniotti, C; Loretelli, C; Meriggi, F; Zaniboni, A; Falcone, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P-291The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status - Trial in progress. (20th June 2018) Authors: Ziranu, P; Demurtas, L; Puzzoni, M; Loupakis, F; Daniele, B; Rimassa, L; Bilancia, D; Lonardi, S; Avallone, A; Pella, N; Ferrari, D; Frassineti, L; Beretta, G; Zaniboni, A; Santoro, A; Zampino, M; Sarobba, M; Zagonel, V; Barni, S; Palmieri, G Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗